AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02611219 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3-Minute Step Test
Description: * Using an aerobic step, the participant walks up and down for a given amount of time with the heart rate being checked before and after~* Using the difference in heart rate and a shortness of breath scale, this test is able to give an estimate of aerobic tolerance
Study NCT02611219 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HSCT Module-Follow Up Adolescent-Self Report (13-18 years)
Description: * 7 question questionnaire about child~* Answers range from 1=all of the time to 5=none of the time
Study NCT00562237 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: S205 10ugHA
Description: 2 i.m. injections per subject (0.5 mL each)
Study NCT00562237 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: S205 30ugHA
Description: 2 i.m. injections per subject (0.5 mL each)
Study NCT00562237 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: S205 10ugHA+500ugAlOH
Description: 2 i.m. injections per subject (0.5 mL each)
Study NCT00562237 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: S205 30ugHA+500ugAlOH
Description: 2 i.m. injections per subject (0.5 mL each)
Study NCT00562237 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: S205 10ugHA+1250ugAlOH
Description: 2 i.m. injections per subject (0.5 mL each)
Study NCT02611219 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HSCT Module-Follow Child-Self Report (5-12 years)
Description: * 10 question questionnaire about child~* Answers range from 1=all of the time to 5=none of the time
Study NCT02611219 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HSCT Module-Follow Up Parent Report-adolescent (13-18 years)
Description: * 7 question questionnaire about child~* 49 question questionnaire about parent~* Answers range from 1=all of the time to 5=none of the time
Study NCT00562237 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: S205 30ugHA+1250ugAlOH
Description: 2 i.m. injections per subject (0.5 mL each)
Study NCT02611219 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HSCT Module-Follow Up Parent Report-School Age (5-12 years)
Description: * 7 question questionnaire about child~* 49 question questionnaire about parent~* Answers range from 1=all of the time to 5=none of the time
Study NCT00675493 — intervention group
Intervention type: DRUG
Intervention: biphasic insulin aspart 30
Description: Start dose and frequency prescribed by the physician as a result of a normal clinical evaluation
Study NCT02749071 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Laparoscopic implantation surgery
Description: Laparoscopic surgery to implant the pulse generator and bipolar lead.
Study NCT02749071 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic implantation surgery
Description: Laparoscopic surgery to implant the pulse generator and bipolar lead.
Study NCT02749071 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EndoStim stimulation for first six months of study
Description: Lower esophageal stimulation
Study NCT02749071 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: EndoStim stimulation from Month 6 thru end of study
Description: Lower esophageal stimulation
Study NCT02749071 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EndoStim stimulation from Month 6 thru end of study
Description: Lower esophageal stimulation
Study NCT02749071 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham EndoStim stimulation for first six months of study
Description: EndoStim device remains off (no stimulation delivered)
Study NCT03140943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib, Thalidomide and Dexamethasone
Description: Carfilzomib will be given on days 1,2,8,9,15,16 in a 4-week (28 day) cycle during induction cycles 1-12, followed by days 1,2,15,16 in a 4-week cycle during maintenance cycles 13-18 (section 4.0) Dexamethasone, 40mg po will be given on days 1,8,15, 22 in a 4-week cycle during induction cycles 1-12, followed by days 1,15, in a 4-week cycle during maintenance cycles 13-18.~Thalidomide, 100mg po will be given daily during induction cycles 1-12 only.
Study NCT00851747 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phosphatidylcholine Deoxycholate
Description: Group A will serve as a control and will receive only injections of saline as a placebo. Group B will receive saline injections on one side of the body and receive study drug injections on the contralateral side. Group C will receive only study drug injections
Study NCT00851747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phosphatidylcholine Deoxycholate
Description: Group A will serve as a control and will receive only injections of saline as a placebo. Group B will receive saline injections on one side of the body and receive study drug injections on the contralateral side. Group C will receive only study drug injections
Study NCT00851747 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Group A will serve as a control and will receive only injections of saline as a placebo. Group B will receive saline injections on one side of the body and receive study drug injections on the contralateral side. Group C will receive only study drug injections
Study NCT00851747 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Group A will serve as a control and will receive only injections of saline as a placebo. Group B will receive saline injections on one side of the body and receive study drug injections on the contralateral side. Group C will receive only study drug injections
Study NCT04395443 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: medication reconciliation
Description: the emergency clinical pharmacists will start medication reconciliation with the admitted patients and a full diseases and preadmission medications history will be taken.A comparison between the accuracy and completeness of drug history lists already presented in the profile and drug history taken by the clinical pharmacists to detect the medication discrepancies
Study NCT02560597 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: repetitive transcranial magnetic stimulation
Description: Stimulation over the epileptogenic focus using variable stimulation protocols as described in literature. This protocol may vary case by case, depending on patient characteristics and achieved effect from previous stimulation.~In absence of effect, rTMS is given on 5 consecutive days at most.
Study NCT02454491 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: intraradial administration of heparin 5000 ui
Study NCT02454491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil
Description: intraradial administration of verapamil 5 mg
Study NCT02215512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RRx-001 + WBRT
Description: Subjects will receive a combination of RRx-001 and whole brain radiotherapy.
Study NCT02560571 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound
Study NCT02560571 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood test
Study NCT02762357 — intervention group
Intervention type: DEVICE
Intervention: Novosyn® Quick
Description: Episiotomy closure
Study NCT01753271 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: thoracic mobilization & shoulder mobilization & exercise
Study NCT01753271 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: shoulder mobilization & exercise
Study NCT01753271 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: shoulder mobilization & exercise
Study NCT00935571 — intervention group
Intervention type: DRUG
Intervention: propofol, remifentanil, sevoflurane
Description: Propofol: using target controlled infusion (TCI); 1-3ug/ml remifentanil: using TCI by 5-20 ng/ml sevoflurane: 2-3volume% (1-2 MAC)
Study NCT00881699 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV Prevention Intervention - Project PRISSMA - HIV I have my eye on you
Description: Eight weekly 2-hour HIV risk reduction intervention sessions, with three weekly 2-hour booster sessions completed 6 months after the initial intervention. Specific goals of the intervention are to (1) increase information about HIV risk behaviors and safer sex options; (2) increase identification of personal risk of HIV and enhance the motivation to engage in safer sex behaviors; and (3) enhance skills to achieve safer sex, particularly negotiating safer sex, using condoms, and communicating within a relationship.
Study NCT00881699 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Promotion Intervention
Description: Eight weekly 2-hour health promotion intervention sessions with three weekly 2-hour booster sessions completed 6 months after the initial intervention. Specific goals of the intervention are to (1) increase information about health issues specific to psychiatric patients, (2) increase identification of personal health risks and enhance motivation to engage in healthier behaviors, and (3) enhance skills to achieve healthier behaviors.
Study NCT04387032 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HVLA Manipulations
Description: The procedure of experimental manipulation: the patient lay on the healthy side with the straight lower limb, and the torso turned towards the dysfunctional side, whose lower limb was bent in the hip and knee joint, and the hands rest on the lower ribs on the same side. The therapist allowed the initial loosening of the tissues and chose the movement barrier with his stabilizing hand. Then, with the treatment hand, he introduced the HVLA thrust through the iliac bone towards the bottom, while giving the iliac bone a posterior or anterior rotation - meaning, the opposite to the occurring dysfunction. If during the manipulation, no cavitation sound was heard, the HVLA thrust was repeated once.
Study NCT04387032 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Manipulation
Description: The sham procedure was the same, but no external force was introduced in the form of a therapeutic impulse.
Study NCT02480998 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-YANG Flu Vaccine QIV 0.5mL
Study NCT02480998 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IL-YANG Flu Vaccine TIV 0.5mL
Study NCT05578313 — intervention group
Intervention type: DRUG
Intervention: Medical Cannabis
Description: Patients will be observed throughout their treatment with medical cannabis, prescribed to them by for clinically treating their disease (treatment is not an intervention of the study).
Study NCT01352845 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rLP2086
Description: 0.5 mL dose, given at 0, 2 and 6 months
Study NCT01352845 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5 mL dose, given at 0, 2 and 6 months
Study NCT01638169 — intervention group
Intervention type: DEVICE
Intervention: adding a heel
Description: walking with and without heels on the gaitrite system
Study NCT04066010 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Mobile application (BP-n-Me)
Description: The mobile app consisted of a series of features including (1) calendar reminders of when to take medications and the patient's antihypertensive medication regimen (2) a Call your Pharmacist button specific to patient's pharmacy, (3) a BP log in which the patient could enter blood pressure values that were automatically compared to goal values, (4) counseling points for lifestyle and adherence factors individually tailored to each patient and (5) lifestyle and medication adherence surveys.
Study NCT03237429 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: bioimpedance spectroscopy
Description: Bioimpedance spectroscopy-The technique involves attaching electrodes to the patient's forearm and ipsilateral ankle, with the patient in a supine position. The BCM measures the body resistance and reactance to electrical currents of 50 discrete frequencies, ranging between 5 and 1000 kHz. Based on a fluid model using these resistances, the extracellular water (ECW), the intracellular water (ICW) and the total body water (TBW) are calculated. These volumes are then used to determine the amount of fluid.~Carotid-femoral pulse wave velocity-will be determined by arterial applanation tonometry using the Sphygmocor system by sequentially recording ECG-gated carotid and femoral artery waveforms.. Pulse wave signals will be recorded by tonometers positioned at the base of the right common carotid artery and over the right femoral artery.
Study NCT03638336 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ILY robotic flexible ureteroscopy
Description: fragmentation of nephrolithiasis
Study NCT02654041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combined T3 and Methimazole treatment
Description: Oral administration of T3 and Methimazole
Study NCT04154397 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cerebellar transcranial stimulation
Description: Feedforward-based training benefits from a dynamic postural task by application of cerebellum transcranial electrical stimulation (ctDCS) of different modes (direct current vs. noise vs. sham) were administered using a one-channel direct current stimulator (NeuroConn DC-Stimulator PlusTM) with study mode enabled for single blinding. Following the baseline trial of posture tracking, participants of three groups were seated in a chair for 20 min to receive either active or sham cerebellar tDCS prior to the posture tracking and transfer test phases.
Study NCT03167125 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Automated Prompts
Description: This intervention is an automated data-driven program, using automated phone calls, text messages, and/or emails, for delivering FIT kit prompts to patients due for colorectal cancer screening. The specific components of the intervention are forthcoming and will be determined using a community-based participatory research approach known as boot camp translation which seeks input from patients and providers.
Study NCT03167125 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Automated Plus Live Prompts
Description: This intervention is a higher-intensity program, using automated data-driven prompts plus linguistically and culturally tailored live prompts, for delivering FIT kit messages to patients due for colorectal cancer screening. The specific components of the intervention are forthcoming and will be determined using a community-based participatory research approach known as boot camp translation which seeks input from patients and providers.
Study NCT00442949 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheterization immediate PCI
Description: Catheterization immediate PCI
Study NCT00442949 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: delayed PCI
Description: delayed PCI
Study NCT01826448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX3397
Study NCT01826448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vemurafenib
Study NCT00702611 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Granulocyte Monocyte Apheresis (GMA-Apheresis)
Description: GMA Apheresis will be performed in a once per week during seven weeks only in experimental arm. Each apheresis will last 60 minutes at a blood flow rate of 30 ml/min.
Study NCT01481506 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Telemonitoring
Description: Use of wearable sensors for heart rate, haemoglobin oxygen saturation, physical activity, respiratory rate with automatic transmission to the monitoring central.
Study NCT04143425 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 3-Tesla conventional magnetic resonance imaging
Description: T1-weighted, T2-weighted, fluid-attenuated inversion recovery, and contrast-enhanced T1-weighted imaging
Study NCT04143425 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Advanced imaging without contrast use
Description: Diffusion-weighted imaging, amide proton transfer-weighted imaging, electrical properties tomography, and 2hG-magnetic resonance spectroscopy
Study NCT04143425 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Dynamic susceptibility contrast-weighted imaging
Description: Cerebral blood volume and vessel architectural imaging parameters
Study NCT00757640 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cholecystectomy
Description: prophylactic cholecystectomy during standard gastric surgery for cancer
Study NCT02019758 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Viscous Budesonide
Description: Oral Viscous Budesonide - 1 mg/4 mL, 4 mL of slurry twice daily
Study NCT02019758 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone MDI
Description: Fluticasone multi-dose inhaler - 4 puffs twice daily (880 mcg, twice daily)
Study NCT02019758 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo slurry
Description: Slurry of sucralose - 4 mL twice daily
Study NCT02019758 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo inhaler
Description: Placebo inhaler - 4 puffs twice daily
Study NCT01865838 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Seprafilm (Sanofi, USA)
Description: Studies have unequivocally shown that Seprafilm is effective in reducing internal adhesion formation after abdominal surgery. In a large scaled randomized controlled trial involving about 1700 patients, Fazio et al. found that the use or Seprafilm reduces the risk of small bowel intestinal obstruction which required operative intervention. The safety profile of Seprafilm has also been nicely demonstrated in a randomized controlled trial by Beck et al. in this study, the authors concluded that within the context of abdomino-pelvic surgery, Seprafilm does not increase the incidence of abdominal/pelvic abscesses in patients after abdomino-pelvic surgery; if anything, the anti-adhesive properties of Seprafilm are such that the authors noted an increased risk of anastomotic complications in patients whose bowel anastomoses were in close contact with Seprafilm.
Study NCT00511108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: sitagliptin phosphate
Description: sitagliptin phosphate 100 mg as oral tablets. Each patient will be administered 1 tablet once daily.
Study NCT03779737 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Muscular Resistance training
Study NCT03779737 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cardiorespiratory training
Study NCT00511108 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: pioglitazone
Description: pioglitazone 30 mg will be supplied as oral tablets. Each patient will be administered 1 tablet once daily.
Study NCT00511108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: pioglitazone
Description: pioglitazone 30 mg will be supplied as oral tablets. Each patient will be administered 1 tablet once daily.
Study NCT00511108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: placebo to pioglitazone
Description: pioglitazone 30 mg placebos will be supplied as oral tablets. Each patient will be administered 1 tablet once daily.
Study NCT03779737 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Habitual training
Study NCT03860662 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Nociceptor flexor reflex
Description: The nociceptive flexion reflex (NFR) is a physiological, polysynaptic reflex allowing for painful stimuli to activate an appropriate withdrawal response
Study NCT00702611 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Granulocyte Monocyte Apheresis (GMA-Apheresis)
Description: GMA Apheresis will be performed in a once per week during seven weeks only in experimental arm. Each apheresis will last 60 minutes at a blood flow rate of 30 ml/min.
Study NCT01010061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: obinutuzumab
Description: 1000 mg obinutuzumab intravenous (IV) infusion, on Days 1 \[first infusion split 100 mg on Day 1 and 900 mg on Day 2 as per protocol amendment\], 8 and 15 in Cycle 1 and Day 1 in Cycles 2-6 (28-day cycles).
Study NCT01010061 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rituximab
Description: 375 mg/m\^2 rituximab intravenous (IV) infusion on Day 1 of Cycle 1 (Cycle duration is 28 days) then 500 mg/m\^2 IV infusions on Day 1 of Cycles 2-6.
Study NCT00511108 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo to pioglitazone
Description: pioglitazone 30 mg placebos will be supplied as oral tablets. Each patient will be administered 1 tablet once daily.
Study NCT00511108 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: placebo to sitagliptin
Description: sitagliptin phosphate 100 mg placebos will be supplied as oral tablets. Each patient will be administered 1 tablet once daily.
Study NCT00511108 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo to sitagliptin
Description: sitagliptin phosphate 100 mg placebos will be supplied as oral tablets. Each patient will be administered 1 tablet once daily.
Study NCT02235168 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: six minute walking test
Study NCT02235168 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: six minute walking test
Study NCT03313856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guazuma Ulmifolia plus Tecoma Stans
Description: Guazuma ulmifolia (313.6 mg) -Tecoma stans (86.4 mg) = 400 mg per capsule
Study NCT03313856 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Calcinaned magnesia
Description: Calcined magnesia 400 mg per capsule